Find the white space before the market does.
Arbitrant maps every clinical trial globally, scores the gaps, and surfaces underserved indications with favorable regulatory pathways — before the competition notices.
Three tools. One intelligence layer.
Each product is built on the same live pipeline — ClinicalTrials.gov, FDA, USPTO, and SEC filings — processed daily and scored by AI.
Scores every disease indication on pipeline density, patient burden, patent proximity, and designation eligibility. Filter, sort, and alert on any gap.
Try it now →Input a molecule profile and indication. Get AI-ranked FDA designation options with historical precedents and timeline impact models.
Request access →Comparable licensing deal data — milestone structures, royalty benchmarks, and M&A multiples for rare and orphan disease. The gap no other tool fills.
Join waitlist →From data to decision in minutes.
Arbitrant does the ingestion, scoring, and alerting — you do the strategy.
The same intelligence — redirected as public good.
Arbitrant’s commercial revenue funds Clincol.org — a free nonprofit that turns the same FDA data into plain-language drug safety education for patients, students, and advocates.
Visit Clincol.org →